Probing the interaction between levamlodipine and hemoglobin based on spectroscopic and molecular docking methods.

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biophysics

Background:

• Levamlodipine (LAML) is a widely used antihypertensive medication.
• The interaction of LAML with blood transport proteins, like hemoglobin, is not well understood.
• Understanding drug-protein binding is crucial for drug efficacy and safety.

Purpose of the Study:

• To elucidate the binding mechanism between levamlodipine (LAML) and bovine hemoglobin (BHb).
• To investigate the influence of co-administered drugs (rofecoxib, propranolol, enalapril) on the LAML-BHb interaction.
• To provide insights into the in vivo transport mechanism of LAML.

Main Methods:

• Spectroscopy techniques (FT-IR, 3D fluorescence)
• Molecular docking simulations
• Molecular dynamics simulations

Main Results:

• A stable complex formed between BHb and LAML, with LAML binding at the β-37 tryptophan site.
• Van der Waals forces and hydrogen bonds were the primary binding forces, with approximately one binding site.
• LAML induced conformational changes in BHb, altering the microenvironment of Trp/Tyr residues.
• Rofecoxib, propranolol, and enalapril increased the binding constant of LAML to BHb without synergistic effects.

Conclusions:

• Levamlodipine (LAML) binds to bovine hemoglobin (BHb) at a specific site, inducing conformational changes.
• The binding affinity of LAML to BHb is modulated by other common drugs.
• This study offers a molecular-level understanding of LAML transport in circulation.